Doximity, Veeva and Omnicell ride surging GenAI adoption in healthcare, tapping digital demand despite market pressure and rising cybersecurity risks.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
高シグナルの見出しのみ — マクロイベント、決算、M&A、規制。リスト記事とアナリストのクリックベイトはデフォルトでフィルタ。1時間ごとに更新。
Doximity, Veeva and Omnicell ride surging GenAI adoption in healthcare, tapping digital demand despite market pressure and rising cybersecurity risks.
According to the average brokerage recommendation (ABR), one should invest in Veeva (VEEV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
In April 2026, Veeva Systems Inc. announced that long-time Senior Vice President and General Counsel Josh Faddis will retire on November 1, 2026, transitioning to a part-time advisory role thereafter. Around the same time, Veeva revealed it will be added to the S&P 500 Index, a milestone that often broadens a company’s investor base and enhances trading liquidity. We’ll now explore how Veeva’s S&P 500 inclusion may influence its investment narrative built around AI integration and...
A number of stocks jumped in the morning session after strong earnings and upbeat forecasts from several peers boosted the broader software sector.